DDX60L is an interferon-stimulated gene product restricting hepatitis C virus replication in cell culture

Journal of Virology

Volumn 89, Issue 20, 2015, Pages 10548-10568

  Grünvogel, Oliver ^a   Esser Nobis, Katharina ^a   Reustle, Anna ^a,d   Schult, Philipp ^a   Müller, Birthe ^a   Metz, Philippe ^a   Trippler, Martin ^b   Windisch, Marc P ^a,e   Frese, Michael ^a,f   Binder, Marco ^c   Fackler, Oliver ^a   Bartenschlager, Ralf ^a   Ruggieri, Alessia ^a   Lohmann, Volker ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^e Institute Pasteur Korea   (South Korea)

^f UNIVERSITY OF CANBERRA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEAD BOX POLYPEPTIDE 60 LIKE PROTEIN; GAMMA INTERFERON; INTERFERON; TRANSCRIPTOME; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; DDX58 PROTEIN, HUMAN; DDX60 PROTEIN, HUMAN; DEAD BOX PROTEIN; ISOPROTEIN; LUCIFERASE; SMALL INTERFERING RNA;

ARTICLE; CONTROLLED STUDY; DEAD BOX POLYPEPTIDE 60 LIKE GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE PRODUCT; GENOME ANALYSIS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INNATE IMMUNITY; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRUS GENE; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS A VIRUS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LIVER CELL; PRIMARY CELL CULTURE; REPLICON; REPORTER GENE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VIROLOGY;

CELL LINE, TUMOR; CELL SURVIVAL; DEAD-BOX RNA HELICASES; GENE EXPRESSION REGULATION; GENES, REPORTER; GENOTYPE; HEPACIVIRUS; HEPATITIS A VIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INTERFERON-GAMMA; LUCIFERASES; PRIMARY CELL CULTURE; PROTEIN ISOFORMS; REPLICON; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTOME; VIRUS REPLICATION;

EID: 84942155960     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01297-15     Document Type: Article

References (71)

1. Hajarizadeh B, Grebely J, Dore GJ. 2013. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10:553-562. http://dx.doi.org/10.1038/nrgastro.2013.107.
2. Thimme R, Binder M, Bartenschlager R. 2012. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev 36:663-683. http://dx.doi.org/10.1111/j.1574-6976.2011.00319.x.
3. Bigger CB, Brasky KM, Lanford RE. 2001. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 75:7059-7066. http://dx.doi.org/10.1128/JVI.75.15.7059-7066.2001.
4. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, Chisari FV. 2002. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 99:15669-15674. http://dx.doi.org/10.1073/pnas.202608199.
5. Liu SY, Sanchez DJ, Aliyari R, Lu S, Cheng G. 2012. Systematic identification of type I and type II interferon-induced antiviral factors. Proc Natl Acad Sci U S A 109:4239-4244. http://dx.doi.org/10.1073/pnas.1114981109.
6. Metz P, Dazert E, Ruggieri A, Mazur J, Kaderali L, Kaul A, Zeuge U, Windisch MP, Trippler M, Lohmann V, Binder M, Frese M, Bartenschlager R. 2012. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology 56:2082-2093. http://dx.doi.org/10.1002/hep.25908.
7. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, Rotman Y, Liang TJ. 2012. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 142:978-988. http://dx.doi.org/10.1053/j.gastro.2011.12.055.
8. Dreux M, Garaigorta U, Boyd B, Decembre E, Chung J, Whitten-Bauer C, Wieland S, Chisari FV. 2012. Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe 12:558-570. http://dx.doi.org/10.1016/j.chom.2012.08.010.
9. Heim MH. 2013. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol 13:535-542. http://dx.doi.org/10.1038/nri3463.
10. Jo J, Aichele U, Kersting N, Klein R, Aichele P, Bisse E, Sewell AK, Blum HE, Bartenschlager R, Lohmann V, Thimme R. 2009. Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 136:1391-1401. http://dx.doi.org/10.1053/j.gastro.2008.12.034.
11. Wieland S, Makowska Z, Campana B, Calabrese D, Dill MT, Chung J, Chisari FV, Heim MH. 2014. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 59:2121-2130. http://dx.doi.org/10.1002/hep.26770.
12. Sheahan T, Imanaka N, Marukian S, Dorner M, Liu P, Ploss A, Rice CM. 2014. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 15:190-202. http://dx.doi.org/10.1016/j.chom.2014.01.007.
13. Gokhale NS, Vazquez C, Horner SM. 2014. Hepatitis C virus. Strategies to evade antiviral responses. Future Virol 9:1061-1075.
14. Randall RE, Goodbourn S. 2008. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89:1-47. http://dx.doi.org/10.1099/vir.0.83391-0.
15. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481-485. http://dx.doi.org/10.1038/nature09907.
16. Metz P, Reuter A, Bender S, Bartenschlager R. 2013. Interferonstimulated genes and their role in controlling hepatitis C virus. J Hepatol 59:1331-1341. http://dx.doi.org/10.1016/j.jhep.2013.07.033.
17. Schoggins JW, MacDuff DA, Imanaka N, Gainey MD, Shrestha B, Eitson JL, Mar KB, Richardson RB, Ratushny AV, Litvak V, Dabelic R, Manicassamy B, Aitchison JD, Aderem A, Elliott RM, Garcia-Sastre A, Racaniello V, Snijder EJ, Yokoyama WM, Diamond MS, Virgin HW, Rice CM. 2014. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505:691-695. http://dx.doi.org/10.1038/nature12862.
18. Fullam A, Schroder M. 2013. DExD/H-box RNA helicases as mediators of anti-viral innate immunity and essential host factors for viral replication. Biochim Biophys Acta 1829:854-865. http://dx.doi.org/10.1016/j.bbagrm.2013.03.012.
19. Fuller-Pace FV. 2006. DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation. Nucleic Acids Res 34:4206-4215. http://dx.doi.org/10.1093/nar/gkl460.
20. Linder P, Jankowsky E. 2011. From unwinding to clamping-the DEAD box RNA helicase family. Nat Rev Mol Cell Biol 12:505-516. http://dx.doi.org/10.1038/nrm3154.
21. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, Foy E, Loo YM, Gale M, Jr, Akira S, Yonehara S, Kato A, Fujita T. 2005. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 175:2851-2858. http://dx.doi.org/10.4049/jimmunol.175.5.2851.
22. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5:730-737. http://dx.doi.org/10.1038/ni1087.
23. Miyashita M, Oshiumi H, Matsumoto M, Seya T. 2011. DDX60, a DEXD/H box helicase, is a novel antiviral factor promoting RIG-I-like receptor-mediated signaling. Mol Cell Biol 31:3802-3819. http://dx.doi.org/10.1128/MCB.01368-10.
24. Khsheibun R, Paperna T, Volkowich A, Lejbkowicz I, Avidan N, Miller A. 2014. Gene expression profiling of the response to interferon beta in Epstein-Barr-transformed and primary B cells of patients with multiple sclerosis. PLoS One 9:e102331. http://dx.doi.org/10.1371/journal.pone.0102331.
25. Oshiumi H, Miyashita M, Okamoto M, Morioka Y, Okabe M, Matsumoto M, Seya T. 2015. DDX60 is involved in RIG-I-dependent and independent antiviral responses, and its function is attenuated by virusinduced EGFR activation. Cell Rep 11:1193-1207. http://dx.doi.org/10.1016/j.celrep.2015.04.047.
26. Lohmann V, Bartenschlager R. 2014. On the history of hepatitis C virus cell culture systems. J Med Chem 57:1627-1642. http://dx.doi.org/10.1021/jm401401n.
27. Windisch MP, Frese M, Kaul A, Trippler M, Lohmann V, Bartenschlager R. 2005. Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J Virol 79:13778-13793. http://dx.doi.org/10.1128/JVI.79.21.13778-13793.2005.
28. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113. http://dx.doi.org/10.1126/science.285.5424.110.
29. Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, Haller O, Bartenschlager R. 2002. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35:694-703. http://dx.doi.org/10.1053/jhep.2002.31770.
30. Friebe P, Boudet J, Simorre JP, Bartenschlager R. 2005. Kissing-loop interaction in the 3' end of the hepatitis C virus genome essential for RNA replication. J Virol 79:380-392. http://dx.doi.org/10.1128/JVI.79.1.380-392.2005.
31. Harak C, Radujkovic D, Taveneau C, Reiss S, Klein R, Bressanelli S, Lohmann V. 2014. Mapping of functional domains of the lipid kinase phosphatidylinositol 4-kinase type III alpha involved in enzymatic activity and hepatitis C virus replication. J Virol 88:9909-9926. http://dx.doi.org/10.1128/JVI.01063-14.
32. Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R. 2003. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol 77:3007-3019. http://dx.doi.org/10.1128/JVI.77.5.3007-3019.2003.
33. Binder M, Quinkert D, Bochkarova O, Klein R, Kezmic N, Bartenschlager R, Lohmann V. 2007. Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic rep-licase chimeras. J Virol 81:5270-5283. http://dx.doi.org/10.1128/JVI.00032-07.
34. Esser-Nobis K, Harak C, Schult P, Kusov Y, Lohmann V. 2015. Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication. Hepatology 62:397-408. http://dx.doi.org/10.1002/hep.27847.
35. Gauss-Müller V, Kusov YY. 2002. Replication of a hepatitis A virus replicon detected by genetic recombination in vivo. J Gen Virol 83:2183-2192. http://dx.doi.org/10.1099/0022-1317-83-9-2183.
36. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Buhler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R. 2011. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 9:32-45. http://dx.doi.org/10.1016/j.chom.2010.12.002.
37. Reiss S, Harak C, Romero-Brey I, Radujkovic D, Klein R, Ruggieri A, Rebhan I, Bartenschlager R, Lohmann V. 2013. The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A. PLoS Pathog 9:e1003359. http://dx.doi.org/10.1371/journal.ppat.1003359.
38. Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, Kallis S, Zayas M, Lohmann V, Luban J, Bartenschlager R. 2009. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog 5:e1000546. http://dx.doi.org/10.1371/journal.ppat.1000546.
39. Kallio MA, Tuimala JT, Hupponen T, Klemela P, Gentile M, Scheinin I, Koski M, Kaki J, Korpelainen EI. 2011. Chipster: user-friendly analysis software for microarray and other high-throughput data. BMC Genomics 12:507. http://dx.doi.org/10.1186/1471-2164-12-507.
40. Esser-Nobis K, Romero-Brey I, Ganten TM, Gouttenoire J, Harak C, Klein R, Schemmer P, Binder M, Schnitzler P, Moradpour D, Bartenschlager R, Polyak SJ, Stremmel W, Penin F, Eisenbach C, Lohmann V. 2013. Analysis of hepatitisCvirus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology 57:953-963. http://dx.doi.org/10.1002/hep.26260.
41. Schmitt M, Scrima N, Radujkovic D, Caillet-Saguy C, Simister PC, Friebe P, Wicht O, Klein R, Bartenschlager R, Lohmann V, Bressanelli S. 2011. A comprehensive structure-function comparison of hepatitis C virus strain JFH1 and J6 polymerases reveals a key residue stimulating replication in cell culture across genotypes. J Virol 85:2565-2581. http://dx.doi.org/10.1128/JVI.02177-10.
42. Hiet MS, Bauhofer O, Zayas M, Roth H, Tanaka Y, Schirmacher P, Willemsen J, Grunvogel O, Bender S, Binder M, Lohmann V, Lotteau V, Ruggieri A, Bartenschlager R. 2015. Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A. J Hepatol http://dx.doi.org/10.1016/j.jhep.2015.04.015.
43. Haller C, Muller B, Fritz JV, Lamas-Murua M, Stolp B, Pujol FM, Keppler OT, Fackler OT. 2014. HIV-1 Nef and Vpu are functionally redundant broad-spectrum modulators of cell surface receptors, including tetraspanins. J Virol 88:14241-14257. http://dx.doi.org/10.1128/JVI.02333-14.
44. Backes P, Quinkert D, Reiss S, Binder M, Zayas M, Rescher U, Gerke V, Bartenschlager R, Lohmann V. 2010. Role of annexin A2 in the production of infectious hepatitis C virus particles. J Virol 84:5775-5789. http://dx.doi.org/10.1128/JVI.02343-09.
45. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408. http://dx.doi.org/10.1006/meth.2001.1262.
46. Frese M, Pietschmann T, Moradpour D, Haller O, Bartenschlager R. 2001. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol 82:723-733. http://dx.doi.org/10.1099/0022-1317-82-4-723.
47. Helbig KJ, Eyre NS, Yip E, Narayana S, Li K, Fiches G, McCartney EM, Jangra RK, Lemon SM, Beard MR. 2011. The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A. Hepatology 54:1506-1517. http://dx.doi.org/10.1002/hep.24542.
48. Martin A, Lemon SM. 2006. Hepatitis A virus: from discovery to vaccines. Hepatology 43:164-172. http://dx.doi.org/10.1002/hep.21052.
49. Marukian S, Andrus L, Sheahan TP, Jones CT, Charles ED, Ploss A, Rice CM, Dustin LB. 2011. Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures. Hepatology 54: 1913-1923. http://dx.doi.org/10.1002/hep.24580.
50. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:1167-1172. http://dx.doi.org/10.1038/nature04193.
51. Binder M, Kochs G, Bartenschlager R, Lohmann V. 2007. Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy. Hepatology 46:1365-1374. http://dx.doi.org/10.1002/hep.21829.
52. al Yacoub N, Romanowska M, Haritonova N, Foerster J. 2007. Optimized production and concentration of lentiviral vectors containing large inserts. J Gene Med 9:579-584. http://dx.doi.org/10.1002/jgm.1052.
53. Tsukiyama-Kohara K, Iizuka N, Kohara M, Nomoto A. 1992. Internal ribosome entry site within hepatitis C virus RNA. J Virol 66:1476-1483.
54. Wang C, Pflugheber J, Sumpter R, Jr, Sodora DL, Hui D, Sen GC, Gale M, Jr. 2003. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 77:3898-3912. http://dx.doi.org/10.1128/JVI.77.7.3898-3912.2003.
55. Lozano G, Martinez-Salas E. 2015. Structural insights into viral IRESdependent translation mechanisms. Curr Opin Virol 12:113-120. http://dx.doi.org/10.1016/j.coviro.2015.04.008.
56. Kuenzel S, Till A, Winkler M, Hasler R, Lipinski S, Jung S, Grotzinger J, Fickenscher H, Schreiber S, Rosenstiel P. 2010. The nucleotidebinding oligomerization domain-like receptor NLRC5 is involved in IFNdependent antiviral immune responses. J Immunol 184:1990-2000. http://dx.doi.org/10.4049/jimmunol.0900557.
57. Chiti F, Dobson CM. 2006. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75:333-366. http://dx.doi.org/10.1146/annurev.biochem.75.101304.123901.
58. Barber GN. 2000. The interferons and cell death: guardians of the cell or accomplices of apoptosis? Semin Cancer Biol 10:103-111. http://dx.doi.org/10.1006/scbi.2000.0313.
59. Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, Stec E, Ferrer M, Strulovici B, Hazuda DJ, Espeseth AS. 2008. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4:495-504. http://dx.doi.org/10.1016/j.chom.2008.10.004.
60. Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, Cui J, Taylor KD, Wilson L, Cummings OW, Chen YD, Rotter JI, Nonalcoholic Steatohepatitis Clinical Research Network. 2010. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology 139:1567-1576. http://dx.doi.org/10.1053/j.gastro.2010.07.057.
61. Comuzzie AG, Cole SA, Laston SL, Voruganti VS, Haack K, Gibbs RA, Butte NF. 2012. Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population. PLoS One 7:e51954. http://dx.doi.org/10.1371/journal.pone.0051954.
62. Morag A, Pasmanik-Chor M, Oron-Karni V, Rehavi M, Stingl JC, Gurwitz D. 2011. Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics 12:171-184. http://dx.doi.org/10.2217/pgs.10.185.
63. Zhang Z, Yuan B, Lu N, Facchinetti V, Liu YJ. 2011. DHX9 pairs with IPS-1 to sense double-stranded RNA in myeloid dendritic cells. J Immunol 187:4501-4508. http://dx.doi.org/10.4049/jimmunol.1101307.
64. Schröder M, Baran M, Bowie AG. 2008. Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J 27:2147-2157. http://dx.doi.org/10.1038/emboj.2008.143.
65. Keskinen P, Nyqvist M, Sareneva T, Pirhonen J, Melen K, Julkunen I. 1999. Impaired antiviral response in human hepatoma cells. Virology 263: 364-375. http://dx.doi.org/10.1006/viro.1999.9983.
66. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, Landthaler M, Landgraf P, Kan S, Lindenbach BD, Chien M, Weir DB, Russo JJ, Ju J, Brownstein MJ, Sheridan R, Sander C, Zavolan M, Tuschl T, Rice CM. 2007. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A 104:12884-12889. http://dx.doi.org/10.1073/pnas.0704894104.
67. Ariumi Y, Kuroki M, Abe K, Dansako H, Ikeda M, Wakita T, Kato N. 2007. DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication. J Virol 81:13922-13926. http://dx.doi.org/10.1128/JVI.01517-07.
68. Owsianka AM, Patel AH. 1999. Hepatitis C virus core protein interacts with a human DEAD box protein DDX3. Virology 257:330-340. http://dx.doi.org/10.1006/viro.1999.9659.
69. Jangra RK, Yi M, Lemon SM. 2010. DDX6 (Rck/p54) is required for efficient hepatitis C virus replication but not for internal ribosome entry site-directed translation. J Virol 84:6810-6824. http://dx.doi.org/10.1128/JVI.00397-10.
70. Jankowsky E. 2011. RNA helicases at work: binding and rearranging. Trends Biochem Sci 36:19-29. http://dx.doi.org/10.1016/j.tibs.2010.07.008.
71. Fuller-Pace FV. 2013. The DEAD box proteins DDX5 (p68) and DDX17 (p72): multi-tasking transcriptional regulators. Biochim Biophys Acta 1829:756-763. http://dx.doi.org/10.1016/j.bbagrm.2013.03.004.